Acumen Pharmaceuticals (ABOS) Operating Income (2020 - 2026)
Acumen Pharmaceuticals (ABOS) reported Operating Income of -$21.1 million for Q1 2026, up 30.36% on a YoY basis from -$16.2 million in Q1 2025, and up 16.07% sequentially from -$25.2 million in Q4 2025.
Acumen Pharmaceuticals (ABOS) Operating Income (2020 - 2026) Analysis & Trends
Acumen Pharmaceuticals (ABOS) has 7 years of Operating Income data on file, last reported at -$21.1 million in Q1 2026.
- For the quarter ending Q1 2026, Operating Income rose 30.36% year-over-year to -$21.1 million; the trailing twelve-month figure through Mar 2026 stood at -$114.6 million (up 9.48% YoY), and the FY2025 full-year result was -$123.8 million, down 8.61% from the prior year.
- Operating Income climbed to -$21.1 million in Q1 2026, from -$25.2 million in the prior quarter.
- In the past five years, Operating Income ranged from a high of -$9.2 million in Q1 2022 to a low of -$41.8 million in Q2 2025.
- A 5-year average of -$21.5 million and a median of -$18.5 million in 2023 frame the typical range for Operating Income.
- Across the five-year window, Operating Income slumped 202.56% in 2022 and soared 36.36% in 2025, its largest moves.
- Tracing ABOS's Operating Income over 5 years: stood at -$14.2 million in 2022, then fell by 29.74% to -$18.5 million in 2023, then tumbled by 114.2% to -$39.6 million in 2024, then soared by 36.36% to -$25.2 million in 2025, then rose by 16.07% to -$21.1 million in 2026.
- Business Quant data shows ABOS's Operating Income at -$21.1 million in Q1 2026, -$25.2 million in Q4 2025, and -$26.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,681.27 Bn | 66,680.98 Bn | - | -27.75 Mn |
| 2 | Nanobiotix | 1,905.61 Bn | 1,905.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,011.81 Bn | 1,011.81 Bn | - | -15.76 Mn |
| 4 | BeOne Medicines | 467.29 Bn | 462.50 Bn | 1.35 Bn | 249.90 Mn |
| 5 | Vertex Pharmaceuticals | 122.89 Bn | 115.65 Bn | 2.59 Bn | 1.14 Bn |
| 6 | Regeneron Pharmaceuticals | 70.28 Bn | 61.53 Bn | 3.31 Bn | 642.90 Mn |
| 7 | Belite Bio | 62.93 Bn | 62.93 Bn | - | -32.68 Mn |
| 8 | Argenx Se | 55.90 Bn | 50.72 Bn | 1.41 Bn | 493.00 Mn |
| 9 | Alnylam Pharmaceuticals | 37.64 Bn | 34.63 Bn | 959.66 Mn | 268.64 Mn |
| 10 | Acumen Pharmaceuticals | 139.40 Mn | 139.40 Mn | - | -21.15 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -21.15 Mn |
| Dec 31, 2025 | -25.20 Mn |
| Sep 30, 2025 | -26.51 Mn |
| Jun 30, 2025 | -41.75 Mn |
| Mar 31, 2025 | -30.37 Mn |
| Dec 31, 2024 | -39.60 Mn |
| Sep 30, 2024 | -32.27 Mn |
| Jun 30, 2024 | -24.38 Mn |
| Mar 31, 2024 | -17.77 Mn |
| Dec 31, 2023 | -18.49 Mn |
| Sep 30, 2023 | -16.04 Mn |
| Jun 30, 2023 | -13.48 Mn |
| Mar 31, 2023 | -13.14 Mn |
| Dec 31, 2022 | -14.25 Mn |
| Sep 30, 2022 | -11.37 Mn |
| Jun 30, 2022 | -10.41 Mn |
| Mar 31, 2022 | -9.21 Mn |
| Dec 31, 2021 | -8.42 Mn |
| Sep 30, 2021 | -3.94 Mn |
| Jun 30, 2021 | -3.44 Mn |